IRLAB Therapeutics AB (publ) (IRLAB-A) — Working Capital to Net Assets Ratio
IRLAB Therapeutics AB (publ) (IRLAB-A) has a Working Capital to Net Assets ratio of -70.4% as of December 2025. Working capital of Skr-21.62 Million (current assets of Skr85.87 Million minus current liabilities of Skr107.49 Million) is measured against net assets of Skr30.72 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See how many days can IRLAB Therapeutics AB (publ) fund operations to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
IRLAB Therapeutics AB (publ) Working Capital to Net Assets (2014–2025)
This chart shows how IRLAB Therapeutics AB (publ)'s Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of December 2025, the ratio stands at -70.4%, reflecting working capital of Skr-21.62 Million against net assets of Skr30.72 Million SEK. For the complete balance sheet picture, see total assets of IRLAB Therapeutics AB (publ).
Annual Working Capital to Net Assets for IRLAB Therapeutics AB (publ) (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for IRLAB Therapeutics AB (publ) from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check IRLAB-A asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -70.4% | Skr-21.62 Million | Skr30.72 Million | Skr85.87 Million | Skr107.49 Million | ▼ -7.6 pp |
| 2024 | -62.8% | Skr-20.48 Million | Skr32.63 Million | Skr79.56 Million | Skr100.04 Million | ▼ -137.8 pp |
| 2023 | 75.0% | Skr86.86 Million | Skr115.76 Million | Skr123.59 Million | Skr36.73 Million | ▼ -6.2 pp |
| 2022 | 81.3% | Skr236.34 Million | Skr290.83 Million | Skr268.68 Million | Skr32.34 Million | ▼ -6.9 pp |
| 2021 | 88.1% | Skr352.04 Million | Skr399.48 Million | Skr421.44 Million | Skr69.40 Million | ▲ +12.6 pp |
| 2020 | 75.5% | Skr262.82 Million | Skr347.88 Million | Skr283.74 Million | Skr20.92 Million | ▲ +22.5 pp |
| 2019 | 53.1% | Skr96.54 Million | Skr181.83 Million | Skr119.88 Million | Skr23.34 Million | ▼ -7.2 pp |
| 2018 | 60.2% | Skr128.01 Million | Skr212.48 Million | Skr140.47 Million | Skr12.46 Million | ▲ +14.9 pp |
| 2017 | 45.3% | Skr70.25 Million | Skr155.00 Million | Skr78.22 Million | Skr7.97 Million | ▲ +26.7 pp |
| 2016 | 18.6% | Skr19.37 Million | Skr103.89 Million | Skr28.19 Million | Skr8.82 Million | ▲ +6.9 pp |
| 2015 | 11.7% | Skr10.79 Million | Skr92.03 Million | Skr16.07 Million | Skr5.28 Million | ▼ -6.1 pp |
| 2014 | 17.8% | Skr15.77 Million | Skr88.57 Million | Skr21.11 Million | Skr5.34 Million | — |